TRIM28 and non-small cell lung carcinoma: In contrast, TRIM28 overexpression conferred resistance to anti-PD-1 therapy (Fig. 2C), further highlighting the significance of TRIM28 expression in maintaining sensitivity to anti-PD-1 therapy in NSCLC.